Opko Health Inc. (OPK)

Trade OPK now with
11/15/2017 7:08:28 AM Xenetic Biosciences Q3 Loss Per Share $0.26 Vs Loss $0.28 Last Year
11/7/2017 8:14:27 AM OPKO Health Submits Premarket Approval Application With FDA For Point-of-Care PSA Test With Claros 1 Platform
11/2/2017 8:05:51 AM Xenetic Biosciences Enters Into Sublicense Agreement Related To Its PolyXen Technology With Baxalta
10/31/2017 9:06:17 AM Xenetic Biosciences Appoints Jeffrey Eisenberg As CEO
10/12/2017 8:09:04 AM OPKO Health Enters Into Exclusive Agreement With Japan Tobacco To Develop And Commercialize RAYALDEE In Japan
9/5/2017 8:15:36 AM Cocrystal Pharma, HitGen And InterX Enter Into Drug Discovery Collaboration
8/15/2017 8:37:53 AM Cocrystal Announces Positive Data From Completion Of Phase 1a/1b Trial Of Non-Nucleoside Polymerase Inhibitor CC-31244
8/15/2017 8:06:20 AM Xenetic Biosciences Q2 Net Loss $2.9 Mln Vs Loss $47.8 Mln Last Year
6/26/2017 8:38:48 AM Xenetic Biosciences Commences Patient Enrollment In Phase 2 Study Evaluating XBIO-101 With Progestin Therapy
6/15/2017 9:16:17 AM OPKO Provides Update To Topline Data Of Phase 3 Clinical Study Of HGH-CTP
5/22/2017 7:03:23 AM MabVax Therapeutics Announces Closing Of $4.1 Mln Public Offering Of Common Stock And Series G Preferred Stock
5/16/2017 7:03:16 AM Xenetic Biosciences Q1 Net Loss $2.9 Mln Vs Net Loss $3.6 Mln Last Year
5/1/2017 8:31:02 AM Xenetic Biosciences Presents Case Study Of PolyXen Platform Technology At The 13th Annual PEGS Boston
4/20/2017 7:37:49 AM Xenetic Biosciences’ PolyXen Platform Technology Accepted For Poster Presentation At 13th Annual PEGS Boston
4/4/2017 7:05:46 AM Xenetic Biosciences Appoints James Parslow As CFO, Effective April 3
4/3/2017 7:42:46 AM Xenetic Biosciences FY Net Loss Applicable To Common Stockholders Widens To $58.2 Mln From $12.5 Mln Last Year
3/28/2017 6:35:28 AM ChromaDex Names Steven Rubin To Board